Skip to content

Primary amyloidosis

The information provided on www.fcarreras.org is intended to support, not replace, the relationship that exists between patients/visitors to this website and their physician.

Information reviewed by Dr. Rocío Parody Porras, Doctor specialising in Haematology. Member of the Management of REDMO (Bone Marrow Donor Registry) and of the Foundation’s medical team. Barcelona Medical Association (Co. 35205)

Primary amyloidosis is a disease originating in the bone marrow, classified within the group of monoclonal gammopathies.

See section Leukaemia, bone marrow and blood cells.

Primary amyloidosis is a disease classified within the group of monoclonal gammopathies. This is a type of cancer in which fibrillar proteins (amyloid substance) are deposited in tissues in sufficient quantities to impair the normal function of the affected organ.

The causes of the production of the amyloid substance and its deposition in tissues are unknown, although primary amyloidosis is related to abnormal production of antibodies by B-lymphocyte-derived cells, the plasma cells.

Primary amyloidosis is a very rare type of neoplasm. Its incidence in Spain is around 9 cases per million inhabitants per year. It tends to affect predominantly older men, with the average age being 65 years.

There is no known direct causative factor for the onset of primary amyloidosis. It is not a contagious disease.

See section Leukaemia, bone marrow and blood cells.

Primary amyloidosis usually has a chronic course and a very slow progression and may remain asymptomatic for years, requiring no treatment.

The main symptoms, once clinically manifested, are tiredness and weight loss, oedema (due to kidney involvement causing nephrotic syndrome in which excessive amounts of protein are lost in the urine), dyspnoea (shortness of breath due to heart failure), enlargement of the liver (hepatomegaly), sensory disorders in the hands and feet (neuropathy), enlargement of the tongue, tendency to hypotension, diarrhoea, impotence, among others. These clinical manifestations are due to organ dysfunction caused by deposits of amyloid material.

The diagnosis of primary amyloidosis is based on the finding of amyloid material in the tissues (by Congo red staining). Blood tests are usually performed, in addition to a biopsy of the abdominal subcutaneous fat (positive in 80% of patients with amyloidosis) and bone marrow (sensitivity of 60-70%). If this biopsy is negative, another rectal or minor salivary gland biopsy would be performed and, if the results are still negative, a biopsy of an affected organ (kidney, endo-myocardium, nerve, liver) depending on the suspicion.

The most common systemic amyloidosis is light chain or AL amyloidosis (74% of systemic amyloidoses), caused by monoclonal light chain fragments usually produced by a small clone of B-cells, and in about 80% of cases the light chain is lambda. However, other less common forms of amyloidosis, such as familial, secondary and senile amyloidosis, with a specific amyloid substance must be ruled out.

It is important, both at diagnosis and during follow-up, to rule out possible organ involvement by amyloid fibrils through clinical history, as well as by determination of biomarkers of cardiac involvement (BNP/proBNP and troponin), together with imaging tests such as echocardiography and cardiac MRI if there are cardiac symptoms, renal (quantification of proteinuria, albuminuria, in 24-hour urine) and serum free light chain ratio, in order to be able to obtain a pre-symptomatic diagnosis. Early diagnosis is key to improving the prognosis of patients with amyloidosis.

The European Commission has approved daratumumab SC in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adult patients with newly diagnosed systemic light chain amyloidosis. This approval makes this daratumumab-based regimen the first approved treatment for AL amyloidosis in Europe. Participation in clinical trials is a priority whenever available.

In parallel, it should be assessed whether the patient is eligible (due to age and organ damage) for an autologous haematopoietic stem cell transplant. In eligible patients, the toxicity of the procedure is acceptable and transplantation can be considered as a first-line therapeutic option or preceded by treatment. Although transplantation can be performed without pre-treatment, pre-transplant induction is often recommended if plasma cell infiltration in the bone marrow > 10% or if delayed transplantation is anticipated. Similarly, patients who are not initially candidates for transplantation may be candidates for transplantation after 2-3 cycles of treatment.

It must be borne in mind that, unfortunately, transplantation does not cure the disease, but it does allow for achieving remissions, sometimes prolonged, and improvement of the affected organs.

In selected cases where cardiac damage is the main limiting factor, cardiac transplantation may be considered followed shortly after by haematopoietic transplantation. It is also not uncommon for the patient to need a kidney transplant, usually following autologous transplantation.

In cases that are not candidates for transplantation (due to little or excessive involvement) treatment is based on the previously mentioned D-VCd scheme, or variants such as CyBorDex (cyclophosphamide, bortezomib and dexamethasone), and BMDex (bortezomib, melphalan dexamethasone). In frailer patients, regimens are reduced to melphalan or cyclophosphamide and dexamethasone, or daratumomab monotherapy as an alternative.

Treatment also includes those specific to visceral involvement such as renal or cardiac failure.

The aim of all treatments is always to slow down the progression of the disease and improve the symptoms as, unfortunately, none of them can cure it.

The prognosis for patients with primary amyloidosis depends largely on the organs affected. However, the absence of a treatment capable of slowing down the deposition and reversing the substance already deposited, and the usual advanced age of the patients, make their prognosis unfavourable.

In Spain there is a large network of associations for haematological cancer patients that, in many cases, can inform you, advise you and even carry out certain procedures. These are the contacts of some of them by Autonomous Communities:

All these organisations are external to the Josep Carreras Foundation.


STATE

  • AMILO (Asociación Española de Amiloidosis)
  • CEMMP (Comunidad Española de Pacientes de Mieloma Múltiple) 
  • AEAL (ASOCIACIÓN ESPAÑOLA DE AFECTADOS POR LINFOMA, MIELOMA y LEUCEMIA)
  • AECC (ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER). Present is the different provinces and in many municipalities. Contact with the nearest branch or call 900 100 036 (24h).
  • AELCLES (Agrupación Española contra la Leucemia y Enfermedades de la Sangre)
  • Josep Carreras Leukaemia Foundation
  • FUNDACIÓN SANDRA IBARRA
  • GEPAC (GRUPO ESPAÑOL DE PACIENTES CON CÁNCER)
  • MPN España (Asociación de Afectados Por Neoplasias Mieloproliferativas Crónicas)


ANDALUCÍA

  • AECC (ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER). Present is the different provinces and in many municipalities. Contact the nearest branch.
  • ALUSVI (ASOCIACIÓN LUCHA Y SONRÍE POR LA VIDA). Sevilla
  • APOLEU (ASOCIACIÓN DE APOYO A PACIENTES Y FAMILIARES DE LEUCEMIA). Cádiz


ARAGÓN

  • AECC (ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER). Present is the different provinces and in many municipalities. Contact the nearest branch.
  • ASPHER (ASOCIACIÓN DE PACIENTES DE ENFERMEDADES HEMATOLÓGICAS RARAS DE ARAGÓN)
  • DONA MÉDULA ARAGÓN


ASTURIAS

  • AECC (ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER). Present is the different provinces and in many municipalities. Contact the nearest branch.
  • ASTHEHA (ASOCIACIÓN DE TRASPLANTADOS HEMATOPOYÉTICOS Y ENFERMOS HEMATOLÓGICOS DE ASTURIAS)


CANTABRIA

  • AECC (ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER). Present is the different provinces and in many municipalities. Contact the nearest branch.


CASTILLA LA MANCHA

  • AECC (ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER). Present is the different provinces and in many municipalities. Contact the nearest branch.


CASTILLA LEÓN

  • ABACES (ASOCIACIÓN BERCIANA DE AYUDA CONTRA LAS ENFERMEDADES DE LA SANGRE)
  • AECC (ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER). Present is the different provinces and in many municipalities. Contact the nearest branch.
  • ALCLES (ASOCIACIÓN LEONESA CON LAS ENFERMEDADES DE LA SANGRE). León.
  • ASCOL (ASOCIACIÓN CONTRA LA LEUCEMIA Y ENFERMEDADES DE LA SANGRE). Salamanca.


CATALUÑA


VALENCIAN COMMUNITY

  • AECC (ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER). Present is the different provinces and in many municipalities. Contact the nearest branch.
  • ASLEUVAL (ASOCIACIÓN DE PACIENTES DE LEUCEMIA, LINFOMA, MIELOMA Y OTRAS ENFERMEDADES DE LA SANGRE DE VALENCIA)


EXTREMADURA

  • AECC (ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER). Present is the different provinces and in many municipalities. Contact the nearest branch.
  • AFAL (AYUDA A FAMILIAS AFECTADAS DE LEUCEMIAS, LINFOMAS; MIELOMAS Y APLASIAS)
  • AOEX (ASOCIACIÓN ONCOLÓGICA EXTREMEÑA)


GALICIA

  • AECC (ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER). Present is the different provinces and in many municipalities. Contact the nearest branch.
  • ASOTRAME (ASOCIACIÓN GALLEGA DE AFECTADOS POR TRASPLANTES MEDULARES)


BALEARIC ISLANDS

  • ADAA (ASSOCIACIÓ D’AJUDA A L’ACOMPANYAMENT DEL MALALT DE LES ILLES BALEARS)
  • AECC (ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER). Present is the different provinces and in many municipalities. Contact the nearest branch.


CANARY ISLANDS

  • AECC (ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER). Present is the different provinces and in many municipalities. Contact the nearest branch.
  • AFOL (ASOCIACIÓN DE FAMILIAS ONCOHEMATOLÓGICAS DE LANZAROTE)
  • FUNDACIÓN ALEJANDRO DA SILVA


LA RIOJA

  • AECC (ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER). Present is the different provinces and in many municipalities. Contact the nearest branch.


MADRID


MURCIA

  • AECC (ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER). Present is the different provinces and in many municipalities. Contact the nearest branch.


NAVARRA

  • AECC (ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER). Present is the different provinces and in many municipalities. Contact the nearest branch.


BASQUE COUNTRY

  • AECC (ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER). Present is the different provinces and in many municipalities. Contact the nearest branch.
  • PAUSOZ-PAUSO. Bilbao


AUTONOMOUS CITIES OF CEUTA AND MELILLA

We also invite you to follow us through our main social media (Facebook, Twitter and Instagram) where we often share testimonies of overcoming this disease.

If you live in Spain, you can also contact us by sending an e-mail to imparables@fcarreras.es so that we can help you get in touch with other people who have overcome this disease.

* In accordance with Law 34/2002 on Information Society Services and Electronic Commerce (LSSICE), the Josep Carreras Leukemia Foundation informs that all medical information available on www.fcarreras.org has been reviewed and accredited by Dr. Enric Carreras Pons, Member No. 9438, Barcelona, ​​Doctor in Medicine and Surgery, Specialist in Internal Medicine, Specialist in Hematology and Hemotherapy and Senior Consultant of the Foundation; and by Dr. Rocío Parody Porras, Member No. 35205, Barcelona, ​​Doctor in Medicine and Surgery, Specialist in Hematology and Hemotherapy and attached to the Medical Directorate of the Registry of Bone Marrow Donors (REDMO) of the Foundation).

Become a member of the cure for leukaemia!

BECOME A MEMBER!
CHARITABLE INITIATIVES
CHARITABLE BEQUESTS

I want to receive the latest news